DOCSLIB.ORG

Intertek Pharmaceutical Services

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Intertek Pharmaceutical Services PHARMACEUTICAL SERVICES Laboratory & Assurance Solutions INTERTEK PHARMACEUTICAL SERVICES Total Quality Assurance for Pharmaceutical Development and Manufacturing Across your product lifecycle, our expertise brings you the insight you need to accelerate pharmaceutical, biopharmaceutical or medical device product development. Our assurance solutions allow you to identify and mitigate risks associated with products, processes, operational and quality management systems, assets and supply chains. Our specialists bring many years of experience across a variety of product areas including: • Innovative and Generic Pharmaceuticals • Orally Inhaled and Nasal Drug Products • Peptides, Proteins • Nutritional Products, Dietary • Biosimilars Supplements • Monoclonal Antibodies • Consumer Healthcare and Cosmetics • Antibody-drug Conjugates • Medical Devices • Oligonucleotide Therapeutics • Veterinary Medicines • Vaccines • Over-the-Counter (OTC) Drugs 2 Achieving Total Quality You can rely on our global network of experts, Assurance laboratories and specialists to deliver support We have delivered flexible including analysis, bioanalysis, formulation Our scientists, regulatory experts and auditors development, biologics characterization, contract services to the work with you at every stage of development specialist inhalation development expertise, global pharmaceutical and manufacturing, providing responsive, regulatory consultancy, risk assessment, quality compliant solutions. auditing and supply chain management industry for over 25 years At Intertek, our wealth of experience and solutions. depth of industry knowledge enables our clients to navigate the challenges of new product development, scale up, manufacturing and market release whilst minimising risks and meeting regulatory criteria accurately. We respond precisely to your needs with solutions that go beyond just “testing” to help you achieve total quality assurance. Laboratory Services Assurance Solutions EARLY STAGE LATE STAGE POST MARKET PRECLINICAL CLINICAL CLINICAL POST APPROVAL SURVEILLANCE & DEVELOPMENT DEVELOPMENT PRODUCTION LABORATORY SERVICES GLP and GCP Bioanalytical Services & Biomarkers GMP and CMC Laboratory Services Pharmaceutical Analysis, Stability and Formulation Development Extractables/Leachables Packaging Support Process Development Analytical Support ASSURANCE SOLUTIONS Toxicology and Impurity Risk Assessment Consulting Product Development Strategies Regulatory Affairs CMC Support & Guidance Toxicology Consultancy Supplier GXP Auditing Solutions, Inspections and Gap Analysis Global Supply Chain Management Solutions & Supply Chain Surveillance Process Quality Audit, Risk Analysis and Process Improvement Environmental Mapping, Inspection and Calibration Process, Facility or Equipment Qualification Sustainability and Asset Integrity Management 3 INTERTEK PHARMACEUTICAL SERVICES Bioanalytical Services With over 20 years of experience conducting regulatory bioanalysis studies, we deliver FDA/EMA compliant bioanalytical solutions that optimise value for your development programs Bioanalysis plays a critical role in the Unique bioanalytical expertise assessment of drug safety and efficacy Our teams are adept in method development, and we understand that each project will method validation and transfer of efficient We apply our bioanalytical present its own unique challenges. Applying and accurate methods which are optimized our 20 years of experience in conducting for your compound. Projects are assigned expertise and industry regulatory bioanalytical studies, our teams to and managed by experienced Principal insight to design strategic work closely with you to ensure that the Investigators with support from teams of best possible solutions are delivered. Project Managers, Project Coordinators, Senior and efficient bioanalytical To help you to make informed decisions Scientists and Chemists. We provide: faster, our Good Laboratory Practice • Bioanalysis for Large and Small Molecules programs (GLP) and Good Clinical Practice (GCP) • Immunogenicity & Neutralizing Antibody compliant laboratories provide clinical Assays kit preparation, sample handling and • Antibody Drug Conjugate (ADC) LC-MS management capabilities, fully integrated and Immunochemistry Services with automated data capture and reporting systems using the latest bioanalytical • Long History of Bioanalytical Support for platforms. Biosimilar Drug Development Our bioanalytical experts have developed • Post Marketing Antidrug Antibody (ADA) methods for thousands of different assays compounds, providing phase-appropriate, • Demonstrated Expertise in Ocular Tissue small molecule and large molecule • Clinical Kit Preparation, Sample Handling & bioanalytical support, high-throughput Management sample bioanalysis, pharmacokinetic, toxicokinetic and pharmacodynamic support, immunogenicity and biomarker assays. Our centres of excellence Our Centre of Excellence in San Diego, CA, USA, spans 46,000 square feet of laboratories, offices and sample storage. Our 30,000 square foot European laboratory is located in Manchester, UK, and together our facilities are positioned to expedite delivery of fast and cost-effective bioanalysis results for global clients. Diverse bioanalytical technologies Our innovative use of technologies means that, no matter how complex your samples, we can accommodate the chemistry or biology of your analytes as well as any matrix interferences. Technologes include immunochemistry, Electrochemiluminescence, GC-MS, LC-MS/MS, qPCR, Nuclear Magnetic Resonance Spectroscopy (NMR), Inductively Coupled Plasma-Mass Spectrometry (ICP-MS) and Surface Plasmon Resonance (SPR). 4 INTERTEK PHARMACEUTICAL SERVICES Large molecule bioanalysis Small molecule LC-MS services CASE STUDY We have extensive experience in the With over 20 years of experience of development, validation, and sample analysis development and validation of quantitative Novel Approaches for An Enzyme of quantitative and qualitative GLP and non- LC-MS/MS methods for novel drugs and Activity Assay regulatory immunoassays in support of clinical metabolites, our scientists deliver robust A client desired an activity assay for a and preclinical studies for therapeutic drugs, and reproducible bioanalysis solutions that PEGylated enzyme for which a commercial synthetic peptides, humanized monoclonal apply validated methods in a high-throughput colorimetric assay was available. The antibodies, chimerics, conjugated drugs, environment to accelerate development colorimetric assay did not meet the growth factors, hormones and cytokines. times for proprietary and generic drugs across performance criteria for regulated work. An many types of biological matrices. We apply immunoassay was then developed but was • Quantitative Ligand Binding Assay regulatory guidelines to a diverse array of subject to significant matrix effects. Capabilities platform technologies including ICP, NMR and • Quantitative ELISAs for Proprietary Our Solution GC. Compounds Development of a replacement assay was • Method Development & Validation complicated by endogenous substrate and • Immunogenicity Studies - High Throughput GLP & GCP Sample enzymatic product.To overcome this, the • Neutralization Cell-based Assay Analysis specificity of LC-MS/MS was employed and Development, Validation and Sample an activity assay developed using a stable Analysis - Pre-clinical & Clinical Bioanalysis labeled substrate which produced a labeled • Radioimmunoassays (RIA), Enzymatic - Bioequivalence & Bioavailability Studies product, which could be differentiated from Assays • Non-GLP Rapid Discovery-Phase the endogenous analyte. • Fluorometric Assays, Luminescence Bioanalysis Benefit Delivered to our Client Assays - In Vitro Screening Bioanalysis A enzymatic activity LC-MS/MS assay was • Biotinylations & Ruthenium Labeling - Tissue Bioanalysis developed and successfully validated to regulatory standards. The method was used • Mode of Action Studies - Early Pharmacokinetic (PK) Studies in multiple pharmacokinetic studies and • Bioanalytical LC-MS/MS for Biologics - Lead Optimization Studies enabled the client to move forward with • Affinity Interactions by SPR • Bioanalysis in Ocular Tissues and Fluids their drug development program. • NMR approaches for PEGylated • Clinical Kit Preparation, Sample Handling & Biomolecules Management • NMR Approaches for PEGylated APIs Biomarker assays • Bioanalysis for trace metals using We deliver discovery and clinical biomarker ICP-MS solutions to support your precision medicine • GC-MS approaches for volatiles strategy enabling you to better predict • Oligonucleotide LC-MS immunochemistry the long-term safety and efficacy of your and immunogenicity. products. Our dedicated biomarker team has expertise in the qualification and validation of biomarkers using ELISA, and ECL platforms (including multiplexing, prototypes and custom multiplexing and Luminex) in multiple matrices and anticoagulants. 5 INTERTEK PHARMACEUTICAL SERVICES GMP and CMC Laboratory Services Through specialist laboratory services for complex products, we help you to accelerate your development process and support your post-marketing requirements Chemistry, manufacturing and controls Stability studies raw material characterisation and sourcing, (CMC) development strategies and Good With a network of ICH stability storage formulation development, scale up, pilot Manufacturing Practice (GMP) laboratory facilities in the UK, USA and Australia, we batch manufacturing and testing, cleaning
Load more

Recommended publications
  • The Gxp Dictionary 1St Edition
    Testo Expert Knowledge The GxP Dictionary 1st edition Definitions relating to GxP and Quality Assurance 1 Note: Some of the information contained in this GxP Dictionary does not apply equally to all countries. Depending on the respective local legislation, other definitions may apply to certain terms and topics. The sections affected are not separately identified. 2 Foreword Efficacy, identity and purity are qual- This GxP Dictionary explains the ity attributes, which are required of majority of terms relating to GxP, products from the GMP-regulated qualification, validation and quality environment. The term “Good Manu- assurance. facturing Practice” sums up the quality assurance requirements from national It is intended as a compact reference and international regulations and laws. guide and aid for all those involved Other GxP forms have now been de- in GMP, and does not purport to be veloped, whose scope also expands complete. to adjacent sectors such as medical devices and life sciences. Testo SE & Co. KGaA The complex requirements of the “GMP compliance” generate a variety of specific concepts and abbrevia- tions. 3 GxP Dictionary Contents Contents 10 Terms and Definitions C 15 Calibration 0-9 15 CAPA 10 21 CFR 210/211 15 Capacity Test 10 483 15 CEP (Certificate of Suitability of Monographs of the European A Pharmacopoeia) 11 Action Limits 15 CFR 11 Active Pharmaceutical Ingredient 15 CFU (Colony-Forming Unit) (API) 16 cGMP 11 ADI (Acceptable Daily Intake) 16 Challenge Test 11 Airlock Concept 16 Change Control 11 Annex 16 Clean Corridor
    [Show full text]
  • Introduction to Medical Device Law and Regulation March 2-4, 2021 | Live Virtual Event Speaker Biographies
    Introduction to Medical Device Law and Regulation March 2-4, 2021 | Live Virtual Event Speaker Biographies DEBORAH BAKER-JANIS joined NSF International in 2013 after working in the medical device industry for over 10 years, including in both regulatory affairs and product development. Her experience includes the development of pre‐clinical testing protocols, risk documentation, quality system and regulatory affairs standard operating procedures, sales training materials, safety reports and domestic and international regulatory strategies and submissions. Ms. Baker‐Janis has supported the development and commercialization of a wide range of products including cardiovascular devices, general and plastic surgery devices, gastroenterology devices and general hospital devices. Her educational background is in biomedical engineering. MAHNU DAVAR is a partner in the Washington, DC office of Arnold & Porter. His practice focuses on assisting FDA-regulated entities with complex regulatory and compliance matters. He has represented early stage medical technology companies, clinical labs, major academic research institutions, and some of the largest multinational drug and device companies in the oncology, ophthalmology, pain, and diabetes care spaces. Mr. Davar routinely counsels clients on the regulatory and compliance aspects of promotional launch campaigns, clinical research, educational grants and charitable giving, manufacturing and supply chain, deal diligence, and other mission-critical activities. He has conducted significant compliance investigations and audits for business operations in the US, Europe, and Asia, and has extensive experience defending companies in criminal and civil healthcare fraud investigations. He has also assisted clients to prepare for and navigate state and federal regulatory inspections. Mr. Davar is a lecturer at the University of Pennsylvania Law School, a Fellow of the Salzburg Global Seminar, and a former Fulbright Scholar to India.
    [Show full text]
  • The Challenge of Compliance in Life Sciences Moving from Cost to Value
    The challenge of compliance in life sciences Moving from cost to value To start a new section, hold down the apple+shift keys and click to release this object and type the section title in the box below. Contents Foreword 1 Executive summary 3 Overview of compliance 4 Compliance insights 6 The future of compliance 18 Glossary 19 Contacts 20 The Deloitte Centre for Health Solutions The Deloitte Centre for Health Solutions, part of Deloitte UK, generates insights and thought leadership based on the key trends, challenges and opportunities within the healthcare and life sciences industry. Working closely with other centres in the Deloitte network, including the US centre in Washington, our team of researchers develop ideas, innovations and insights that encourage collaboration across the health value chain, connecting the public and private sectors, health providers and purchasers, and consumers and suppliers. In this publication, references to Deloitte are references to Deloitte LLP, the UK member firm of DTTL. To start a new section, hold down the apple+shift keys and click to release this object and type the section title in the box below. Foreword Welcome to the Deloitte UK Centre for Health Solutions’ report on The challenge of compliance in life sciences: Moving from cost to value. Seeing the challenges that life sciences clients face in responding to an increasingly complex regulatory environment led us to launch an independent research initiative which set out to identify: • how well the industry understands the totality of its compliance risks • how compliance is managed and implemented within life sciences companies • what the future of compliance looks like.
    [Show full text]
  • Quality Management System (QMS) for Apis
    Quality Management System (QMS) for Active Pharmaceutical Ingredients (API) Manufacturers integrating GMP (ICH Q7a) into ISO (9001: 2000) September 2005 APIC / CEFIC Quality Management System - integrating GMP (ICH Q7a) into ISO (9001: 2000) Page 2 of 73 Table of Contents I. Introduction II. Objective and Scope III. Quality Management Systems for API manufacturers 1. Quality Management System 2. Management responsibility 3. Resource management 4. Product realization (Manufacturing Operations) 5. Measurement, analysis and improvement (Evaluation Activities) IV. Supplementary Information 1. Identification of system approaches in Q7a 2. Description of processes 3. Structure of a Quality Manual 4. Cross-reference of APIC QMS documents (from “old” to “new”) 5. Assistance for implementation of a QMS 6. Matrix GMP(Q7a) / ISO (9001:2000) V. Glossary VI. Abbreviations VII. References VIII. Acknowledgements APIC / CEFIC Quality Management System - integrating GMP (ICH Q7a) into ISO (9001: 2000) Page 3 of 73 I. Introduction The changing regulatory environment In a Science Board Meeting held in November 2001, FDA raised some concerns regarding the efficiency of the pharmaceutical industry. The factors contributing to this situation were identified as follows: • Pharmaceuticals are complex, multivariate physicochemical systems that are - Often treated (during development) as univariate systems (one-factor-at-a-time, trial- and-error experimentation) - Physical properties of materials normally not well characterized - Equipment selection based on tradition - Process factors are not well understood • Development is done under time crunch • Post approval changes require regulatory oversight It was said that a higher efficiency is required in order to provide high quality drugs to the market in a timely manner, to successfully take advantage of the new drug development opportunities offered by advances in chemistry and biology.
    [Show full text]
  • Gxp Regulations for Healthcare
    Understanding GxP Regulations for Healthcare GxP Guidelines What is GxP? GxP is a collection of quality guidelines and regulations created to ensure that bio/pharmaceutical products are safe, meet their intended use, and adhere to quality processes during manufacturing, control, storage, and distribution. GxP was established by the Food and Drug Administration (FDA) and encompasses different standards recognized as: G – stands for “Good” P – stands for “Practice” x – variable depending on the application. It can be M for “Manufacturing”, C for “Clinical”, L for “Laboratory”, S for “Storage”, D for “Distribution”, R for “Review”, etc. Understanding GxP Regulations for Healthcare | 2 GxP ensures that regulated organizations comply with specific and secure manufacturing and storage processes and procedures which determine effective research standards for non-clinical laboratory trials and safe human-subject clinical trials. GxP’s guidelines focus on 1 : • Traceability: the ability to reconstruct the development history of a drug or medical device. • Accountability: the ability to resolve who has contributed what to the development and when. • Data Integrity (DI): the reliability of data generated by the system. DI could be determined by the following activities: » Identifying the data generated by the system during critical processes (data flow diagram) » Defining the DI requirements (e.g. ALCOA data attributes) during the lifecycle of data » Identifying the risks and mitigation strategies (e.g. technical or procedural controls) to avoid DI breaches. Who is impacted by GxP? Regulated industries including food, pharma, medical devices, and cosmetics are impacted by GxP. GxP guidelines and regulations are global; some of the popular regulators include FDA in the US, TGA in Australia, and HS-SC in Canada.
    [Show full text]
  • Annex 2 WHO Good Manufacturing
    Annex 2 WHO good manufacturing practices for pharmaceutical products: main principles1 Introduction 79 General considerations 80 Glossary 81 Quality management in the medicines industry: philosophy and essential elements 85 1. Pharmaceutical quality system 85 Quality risk management 88 Product quality review 88 2. Good manufacturing practices for pharmaceutical products 90 3. Sanitation and hygiene 91 4. Qualification and validation 91 5. Complaints 92 6. Product recalls 93 7. Contract production, analysis and other activities 94 General 94 The contract giver 94 The contract acceptor 95 The contract 96 8. Self-inspection, quality audits and suppliers’ audits and approval 97 Items for self-inspection 97 Self-inspection team 98 Frequency of self-inspection 98 Self-inspection report 98 Follow-up action 98 Quality audit 98 Suppliers’ audits and approval 98 1 The current document is a revision of WHO Good manufacturing practices for pharmaceutical products: main principles, previously published in WHO Technical Report Series, No. 961, 2011, Annex 3. 77 WHO Expert Committee on Specifications for Pharmaceutical Preparations Forty-eighth report 9. Personnel 99 General 99 Key personnel 99 10. Training 103 11. Personal hygiene 103 12. Premises 104 General 104 Ancillary areas 105 Storage areas 106 Weighing areas 106 Production areas 107 Quality control areas 108 13. Equipment 108 14. Materials 109 General 110 Starting materials 110 Packaging materials 111 Intermediate and bulk products 112 Finished products 112 Rejected, recovered, reprocessed and reworked materials 112 Recalled products 113 Returned goods 113 Reagents and culture media 113 Reference standards 114 Waste materials 114 Miscellaneous 115 15. Documentation 115 General 115 Documents required 116 16.
    [Show full text]
  • Handbook Good Laboratory Practice (Glp)
    Special Programme for Research & Training in Tropical Diseases (TDR) sponsored by UNICEF/UNDP/World Bank/WHO SECOND EDITION Special Programme for Research & Training in Tropical Diseases (TDR) sponsored by UNICEF/UNDP/World Bank/WH O HANDBOOK GOOD LABORATORY PRACTICE (GLP) Quality practices for regulated non-clinical research and development WHO Library Cataloguing-in-Publication Data Handbook: good laboratory practice (GLP): quality practices for regulated non-clinical research and development - 2nd ed. 1.Laboratories - organization and administration. 2.Laboratories - handbooks. 3.Laboratories techniques and procedures. 4.Manuals. I.UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases. ISBN 978 92 4 154755 0 (NLM classification: QY 25) Copyright © World Health Organization on behalf of the Special Programme for Research and Training in Tropical Diseases 2009 All rights reserved. The use of content from this health information product for all non-commercial education, training and information purpos- es is encouraged, including translation, quotation and reproduction, in any medium, but the content must not be changed and full acknowledgement of the source must be clearly stated. A copy of any resulting product with such content should be sent to TDR, World Health Organization, Avenue Appia, 1211 Geneva 27, Switzerland. TDR is a World Health Organization (WHO) executed UNICEF/UNDP/World Bank/World Health Organization Special Programme for Research and Training in Tropical Diseases. The use of any information or content whatsoever from it for publicity or advertising, or for any commercial or income-gen- erating purpose, is strictly prohibited. No elements of this information product, in part or in whole, may be used to promote any specific individual, entity or product, in any manner whatsoever.
    [Show full text]
  • 19Th APIC/CEFIC European Conference on Active Pharmaceutical Ingredients
    Europe‘s Active Pharmaceutical leading APIC a sector group of Ingredients Committee API Conference Authority Speakers: Hélène Bruguera EDQM, France Brendan Cuddy EMA, United Kingdom Graeme McKilligan MHRA, United Kingdom th 19 APIC/CEFIC European Conference on Jean-Louis Robert Chairman of the EMA QWG, United Kingdom Industry Speakers:: ACTIVE Richard M. Bonner United Kingdom Tom Buggy DSM Corporate Operational PHARMACEUTICAL Audit, The Netherlands Graham Cook Pfizer, United Kingdom INGREDIENTS Marieke van Dalen Aspen Oss B.V., The Netherlands Ralf Gengenbach Barcelona, Spain Gempex, Germany Roisin Hickey 23 - 25 November 2016 Hovione, Ireland George Hartong van Lokven Aspen Oss B.V., The Netherlands Graca Mata GMP Conference Hovione, Portugal Rudy Peeters 23 - 24 November 2016 Janssen Pharmaceutica, Belgium Colin Rienewerf Piramal, United Kingdom Regulatory Affairs Conference Anthony Storey Pfizer, United Kingdom 24 - 25 November 2016 Francois Vandeweyer Janssen Pharmaceutica, Belgium Hilde Vanneste Janssen Pharmaceutica, Belgium Lore Vignoli Roquette Freres, France Victoria Waddington Macfarlan Smith Limited A Johnson Matthey Company, United Kingdom Helen Xue Intertek Chemicals & Pharmaceuticals China 19th APIC/CEFIC European Conference on Active Pharmaceutical Ingredients Objectives of the Conference ant manufacture of APIs, the FDA’s Quality Metrics program, The APIC/CEFIC Conference on Active Pharmaceutical Ingredi- quality risk management in global API supply chains and data ents is Europe’s leading event. Many major stakeholders from integrity issues. Authorities and the Industry are each year joining this Confer- ence. Speakers from FDA, EMA, EDQM, National Authorities, In the Joint GMP and Regulatory Affairs part of the conference from Industry and Industry Associations will discuss the latest you will hear presentations about the ICH Q11 regulatory start- developments in the field of GMP and Regulatory Compliance.
    [Show full text]
  • Statutory Report on Corporate Social Responsibility 2020
    Growing as a leader in peptide therapeutics Zealand Pharma Corporate Responsibility Report 2020 Company reg. no. 20045078 Contents Zealand Pharma ∞ Corporate Responsibility Report 2020 2 Contents Corporate Responsibility Report 2020 Changing lives 3 Transforming peptides 4 Our business model 5 Focus on Corporate Responsibility 6 Our People 7 Quality 10 Patients 11 Environment 13 Ethics 14 About this Report This statutory report on corporate social and environmental responsi- bility is for the financial year 2020, cf. section 99a and 99b of the Danish Financial Statements Act. This report is a supplement to the management’s review in the Annual Report 2020 covering the period January 1 to December 31, 2020. Changing lives Zealand Pharma ∞ Corporate Responsibility Report 2020 3 Changing lives We work every day with patient There are over 300 million people living with communities and thought leaders one or more of over 6,000 identified rare to change the lives of people with diseases around the world1, each supported Peptides have proven severe medical conditions. by family, friends and a team of to be effective drugs caregivers that make up the rare in a number of disease community. Many of these different diseases, with diseases are life threatening, with significant untapped no available therapy to help these potential across many patient groups therapy areas.² SDG 3: Ensure healthy lives and promote well- being for all at all ages We are passionate about changing the lives of people with severe medical conditions through targeted development of Our ambition is to be next generation peptide a world leader in treating therapeutics.
    [Show full text]
  • Statutory Report on Corporate Social Responsibility 2018
    Clear path ahead Zealand Pharma Corporate Social Responsibility Report 2018 Anders Stensbjerg Kristensen Company reg. no. 20045078 lives with type 1 diabetes 2 Zealand Pharma ∞ Corporate Social Responsibility Report 2018 Contents About this Report We believe in operating as a responsible company that serves broader economic, societal, and environmental interests. In addition to contributing to the sustainability Corporate Social Responsibility of the world in which we live and work, Report 2018 acting responsibly will further our ability to develop meaningful and similarly Zealand in brief 3 sustainable relationships with customers, suppliers, investors, and key stakeholders Our Ambition and Business Model 4 including current and future employees. Focus on Corporate Social Responsibility 5 This statutory report on corporate social responsibility is for the financial year Commitment to Sustainable 2018, cf. section 99a and 99b of the Danish Development Goals 7 Financial Statements Act. This report is a Employees 8 supplement to the Management’s review in the Annual Report 2018 covering the period Diversity 11 January 1 – December 31, 2018. Quality 13 Patients 14 Environment 17 Ethics 18 Zealand Pharma ∞ Corporate Social Responsibility Report 2018 3 We are passionate about changing the Zealand lives of people living with severe medical conditions through targeted development in brief of next generation peptide therapeutics. To achieve this ambition, our organization is Changing lives with rapidly maturing towards a fully integrated Danish Leading Peptide biotech company with commercial Biotech Platform next generation peptide operations in the U.S. therapeutics. Founded in Copenhagen A world leading peptide We have four late stage programs with the (HQ) in 1998, opened U.S.
    [Show full text]
  • Microsoft Office 365 Gxp Guidelines
    Microsoft Office 365 GxP Guidelines White paper Microsoft Office 365 GxP Guidelines DISCLAIMER © 2019 Microsoft Corporation. All rights reserved. This document is provided "as-is". Information and views expressed in this document, including URL and other internet website references, may change without notice. In addition, for your convenience, this document references one or more Microsoft agreements and summarizes portions of such agreements. You should refer to the actual text in the most current version of the Microsoft agreements for the exact legal commitments. This document does not constitute legal advice; you should consult your own counsel for legal guidance on your specific scenarios. This document does not provide you with any legal rights to any intellectual property in any Microsoft product. You may copy and use this document for your internal, reference purposes. You bear the risk of using it. April 2019 Page 2 of 76 Microsoft Office 365 GxP Guidelines Foreword Cloud computing is an essential part of every organization’s IT strategy. Life sciences and pharmaceutical companies are no exceptions. Across the board, innovative partners and customers in the life sciences industry have embraced Microsoft Office 365 as a critical engine for digital transformation—one that can shorten the time to market, and that has the potential to drive whole new categories of products and services. Each year Microsoft invests billions of dollars in designing, building, and operating innovative cloud services. But trust is not a product – it’s a value that we must earn every day, every month, and every year. Microsoft cloud services are built around key tenets of security, privacy, transparency, and compliance, and we invest more each year to increase the confidence of our life sciences customers in Microsoft cloud services.
    [Show full text]
  • Digitalization of Documents in a Gxp- Regulated Environment
    Digitalization of Documents in a GxP- Regulated Environment Digitization of Documents in a GxP-Regulated Environment 1st Edition Edited by the German Society for Good Research Practice (DGGF) (Deutsche Gesellschaft für Gute Forschungspraxis e.V.) Version: 1 Date: Dezember 12th, 2011 March 1st , 2012 (English translation) Digitization of Documents in a GxP-Regulated Environment 1st Edition Edited by the German Society for Good Research Practice (DGGF) (Deutsche Gesellschaft für Gute Forschungspraxis e.V.) Authors: Michael Bursian, Grünenthal GmbH Thorsten Dunker, Biomedion GmbH Britta Krusemeyer, Covance Laboratories GmbH Klaus Lindow, Bayer Schering P harma AG Bernd Mohnsame, Z.A.S. Zentral Archiv Service GmbH Bettina Quernheim, Sanofi Aventis Deutschland GmbH Summary As soon as you start dealing with the possibilities of digitizing documents in a GxP-regulated environment, you very quickly realize that there are no detailed guidelines for the conversion. Therefore, in a working group, con- sisting of representatives of archive service providers, IT service providers, contract research providers and the pharmaceutical industry, we have investigated whether the current legal situation in the various GxP sectors allow to digitize documents and then destroy the originals. In a second step, we have described the requirements imposed on the digitization process from practice. In all GxP sectors, the preparation of copies and their use instead of the originals is possible in principle. However, there must be a documented check of the result of the copying process. We suggest that this procedure should be transferred to the digitization and the degree of detail of the checking should be planned on the basis of a risk analysis.
    [Show full text]